Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 147, Issue 1, 2009, Pages 101-105

  Ferron, Jean Guillaume ^a   Uzan, Catherine ^a   Rey, Annie ^a   Gouy, Sebastien ^a   Pautier, Patricia ^a   Lhommé, Catherine ^a   Duvillard, Pierre ^a   Morice, Philippe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Histological response; Interval debulking surgery; Neoadjuvant chemotherapy; Ovarian cancer; Unresectable tumour

Indexed keywords

PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 71749111452     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.07.016     Document Type: Article

References (24)

1. Griffiths T.C., Parker L.M., and Fuller A.F. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63 (1979) 235-240
2. Bristow R.E., Tomacruz R.S., Armstrong DK., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
3. Eisenkop S.M., Spirtos N.M., Montag TW., et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
4. Van der Burg M.E., Van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332 (1995) 629-634
5. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 1030 (2006) 1070-1076
6. Le T., Shahriari P., Hopkins L., Faught W., and Fung Kee Fung M. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer 16 (2006) 986-990
7. Le T., Williams K., Senterman M., et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 106 (2007) 160-163
8. Le T., Williams K., Senterman M., Hopkins L., Faught W., and Fung-Kee-Fung M. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 14 (2007) 2649-2653
9. Sassen S., Schmalfeldt B., Avril N., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38 (2007) 926-934
10. Morice P., Brehier-Ollive D., Rey A., et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-nonexposed study. Ann Oncol 14 (2003) 74-77
11. Morice P., Dubernard G., Rey A., et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197 (2003) 955-963
12. Lhommé C., Joly F., Walker J.L., et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26 (2008) 2674-2682
13. Cure H., Battista C., Guastalla J.P., et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc ASCO 22 450s (2004) A5006
14. Raymond A.K., Chawla S.P., Carrasco CH., et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4 (1987) 212-236
15. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 (2005) 9304-9311
16. Rajan R., Esteva F.J., and Symmans W.F. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer 5 (2004) 235-238
17. Ogston K.N., Miller I.D., Payne S., et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12 (2003) 320-327
18. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25 (2007) 4414-4422
19. Becker K., Mueller J.D., Schulmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98 (2003) 1521-1530
20. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. Cancer 73 (1994) 2680-2686
21. Schneider P.M., Baldus S.E., Metzger R., et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242 (2005) 684-692
22. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 (2006) 559-564
23. Aletti G.D., Dowdy S.C., Gostout B.S., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107 (2006) 77-85
24. Tiersten A., Liu P., Smith H., et al. Phase II evaluation of neoadjuvant chemotherapy and interval debulking surgery followed by intraperitoneal chemotherapy in women with stage III and IV epithelial, fallopian tube, or primary peritoneal cancer: a Southwest Oncology Group study. Gynecol Oncol 108 Suppl. 1 (2008) S3